Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-443-7 | CAS number: 95-71-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- HYPOTHESIS FOR THE ANALOGUE APPROACH
Common functional group(s) and common mechanism(s) of action.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 006
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EPA OPPTS 870.3100 (90-Day Oral Toxicity in Rodents)
- Deviations:
- not specified
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Hydroquinone
- EC Number:
- 204-617-8
- EC Name:
- Hydroquinone
- Cas Number:
- 123-31-9
- Molecular formula:
- C6H6O2
- IUPAC Name:
- hydroquinone
- Test material form:
- solid: particulate/powder
Constituent 1
- Specific details on test material used for the study:
- The purity of the sam ples was at least 99, and the mass spectrum was consistent with the structure of HQ.
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- For these acute oral toxicity and subehrenie studies, male and female Sprague-Dawley rats were obtained from Charles River Laboratories (Wilmington, MA).
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- test solution was prepared daily
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 5 days per week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 20 mg/kg bw/day (nominal)
- Dose / conc.:
- 64 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10 male and 10 female rats were randomly assigned to each of three test groups and one control group.
- Control animals:
- yes
- Details on study design:
- The purpose of the subchronic study was to evaluate the neurotoxic and nephrotoxie potential of HQ in the Sprague-Dawley rat following subchronic exposure at acutely toxie dose levels using an observational battery to evaluate tbe nervous system for functional deficits and by
using histopathology to detect morphological changes in the CNS, PNS, and kidneys. - Positive control:
- not stated
Examinations
- Observations and examinations performed and frequency:
- According to this newly added data, no adverse effects on the kidney were reported in male and female Sprague-Dawley rats treated in groups of 10 animals by gavage with 0, 20, 64 or 200 mg/kg BW/day hydroquinone in distilled water, 5 days per week for 13 weeks. Neuro-histopathology was conducted on various brain areas. Mild, transient tremors and reduced home-cage activity were observed in the mid- and high-dose groups im-mediately after dosing with the incidence increased in a dose-dependent manner, no more detailed quantitative data were reported). No differences in body weight, feed consumption, and brain or kidney weight were noted. Morphologic lesions associated with the treatment were not observed
- Sacrifice and pathology:
- The kidneys of the high dose and control male rats were also processed for histopathology.
No treatment related changes at gross necropsy. - Statistics:
- For the subchronic study, mean data were evaluated for statistical significance using the following statistical tests: one-way analysis of variance
(ANOVA, p 6 0.05), Bartlett’s test (p 6 0.01), and Duncan’s multiple range test (p 6 0.05). Organ weights from perfused and unperfused animals
were analyzed separately. Prior to analyzing counts of defecations, urinations, and vocalizations, the data were transformed to make the
variances independent of the means (Sokal and Rohlf, 1969; Daniel, 1978).
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- In this study, repetitive acute CNS stimulation did not result in evidence of subchronic neurotoxicity as assessed by FOB examinations.
Tremors were routinely observed shortly after dosing both males and females with 64 or 200 mg/kg HQ, and depression of general activity
was also noted at the 200 mg/kg HQ dose level. Tremors were observed as a fine shaking or trembling of the body or in mild cases, just the ears. Tremors appeared in the 200 mg/kg males between 30 min and 1 h after dosing and in the 200 mg/kg females, between 4 and 25 min. Minimal to minor tremors were observed in all 200 mg/kg animals, all 64 mg/kg females, and in 7/10 64 mg/kg males. Recovery from the tremors was rapid. - Mortality:
- no mortality observed
- Description (incidence):
- within the applied doses no mortality was observed.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- For the 200 mg/kg males, a slightly lower mean body weight relative to control was observed from Day 1 until termination of the study; this difference was not significant
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Feed consumption for the 200 mg/kg males was significantly lower than the control between Days 0 and 4. Thereafter, feed consumption for
the 200 mg/kg males increased to a level comparable to controls. Feed consumption and body weights were comparable to controls throughout the study for all other HQ groups. - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Brown discolored urine stains of minor intensity were observed on the paper under the home cages of all surviving rats between the day of dosing (Day 0) and Day 2.
- Behaviour (functional findings):
- effects observed, treatment-related
- Description (incidence and severity):
- Behavioral changes associated with HQ exposure were observed primarily during the 1 and 6 h FOB examinations (Table 2). Changes were observed in both sexes, although not in an identical manner. Among cage-side observation parameters, males showed a significant decrease in home cage activity during the 6 h FOB (6/10 males at 200 mg/ kg vs. none of the controls). The incidence of decreased activity was also greater for the 64 mg/kg males at the 6 h FOB, but this difference was not significant. A significant decrease in activity level while the animals were being
removed from the cage was seen among females: at the 1 h FOB, all ten 200 mg/kg females were affected compared with 6/10 control animals. HQ-related changes observed - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No treatment-related changes were observed at gross necropsy of any of the HQ-treated animals and no HQ-related histologic changes were present in the kidneys from any of the HQ-exposed animals.
- Neuropathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Neuropathology examination revealed that the sciatic nerve of one control female contained a focal area of fibrosis with a minor decrease in the number of axons. A second control female had a single group of myelin ovoids present in the tibial nerve. One 200 mg/kg female had single degenerating axons in the sciatic and tibial nerves. One male control animal had two degenerating axons in the plantar nerve and one 200 mg/kg male had a single group of myelin ovoids in the tibial nerve. None of these changes were considered related to HQ.
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not specified
Effect levels
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- 64 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- clinical signs
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 64 mg/kg bw/day (actual dose received)
- System:
- nervous system
- Organ:
- brain
Applicant's summary and conclusion
- Conclusions:
- For Hydroquinone a LOAEL of 64 mg/kg bw was derived.
- Executive summary:
Repetitive doses of HQ resulted in transient tremors and reduced motor activity levels following daily treatment and during the functional observational battery examinations performed shortly after administration of P64 mg/kg HQ, but not 20 mg/kg. The threshold for CNS stimulation appears to be very close to 64 mg/kg because the effects were just barely detectible in this study and were not detectible in F-344 rats given 100 mg/kg for 13 weeks or 50 mg/kg for 2 years. In this study, repetitive acute CNS stimulation did not result in evidence of subchronic neurotoxicity as assessed by FOB examinations, quantitative grip strength measurement, brain weight, or neuropathology examinations. In addition, no nephropathy was evident in Sprague-Dawley rats given 200 mg/kg HQ; a dose level that is nephrotoxic to F-344 rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.